Fresh analysis reveals that people who stop using popular weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass far faster than those who stop traditional lifestyle programs.
Published data in a major medical journal demonstrates that while obese people often shed about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these medications need to be cognizant of the danger of quick weight regain when the medication concludes," stated expert Dr. Susan Jebb.
Such speed of regain means a reversion to starting mass within about 18 months.
Comparing Therapies
The analysis, which examined dozens of trials involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
Researchers emphasize that people who lose weight through lifestyle changes alone usually see a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Nutrition scientists propose the mechanism of the injections is key to understanding the heightened weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating far more likely."
An Ongoing Condition?
Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, considering the high risk of weight regain, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who say that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the jabs report a powerful resurgence of appetite.
"It was like a switch activating and I was suddenly starving," recalled a patient.
The struggle is exacerbated if individuals have not developed sustainable lifestyle or habit modifications during treatment.
Significant Interest
Figures show that millions of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and long-term success hinges on integrated behavioural support.
